RxDoctor Payments DataLook up a doctor →

Denine Raymond

Nurse Practitioner · Rock Hill, SCNPI 1528611357

Payments from drug & device makers

$8,606in general payments, 2019–2025

Across 482 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$825
  • Sanofi-aventis U.S. LLC$669
  • Lilly USA, LLC$637
  • Astellas Pharma US Inc$495
  • Amgen$468
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,54499%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,606 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$126,367
Medicare patients
453
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$42,875
OzempicSemaglutide22$33,764
EliquisApixaban24$29,281
LinzessLinaclotide17$12,651
JanuviaSitagliptin Phosphate17$11,115
TrintellixVortioxetine Hydrobromide11$7,003
Breo ElliptaFluticasone/Vilanterol15$6,748
Rosuvastatin Calcium328$5,577
Pramipexole ErPramipexole Di-Hcl12$4,973
Levothyroxine Sodium232$2,926
SynthroidLevothyroxine Sodium19$1,951
Losartan Potassium163$1,861
Bupropion XlBupropion Hcl47$1,849
Famotidine122$1,839
Atorvastatin Calcium154$1,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$252$42,87542 claims
Novo NordiskOzempic$1,577$33,76422 claims
PfizerEliquis$127$29,28124 claims
AbbVieLinzess, Synthroid$825$14,60236 claims
MerckJanuvia$167$11,11517 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$225$7,00311 claims
GSKBreo Ellipta$146$6,74815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$2,926232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →